Edwards Lifesciences Corporation (NYSE:EW) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Edwards Lifesciences, with 17 buy ratings and 6 hold ratings among 23 firms. The average 12-month price target is $100.27, implying upside from the reported $90.86 share price.
• Edwards reported quarterly EPS of $0.78, topping the $0.74 consensus estimate, while revenue rose 13.6% year over year to $1.74 billion. The company guided for third-quarter 2026 EPS of $0.71–$0.77 and full-year EPS of $2.95–$3.05.
• Company insiders sold 5,045 shares worth approximately $457,749 over the past three months, while institutional investors own 79.46% of Edwards Lifesciences’ outstanding stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-three research firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $100.2727.

EW has been the topic of a number of research reports. JPMorgan Chase & Co. upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Mizuho raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Monday, July 13th.

Edwards Lifesciences Stock Up 0.7%

NYSE:EW opened at $90.86 on Tuesday. The stock's fifty day moving average price is $89.64 and its two-hundred day moving average price is $85.18. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a market cap of $52.32 billion, a price-to-earnings ratio of 52.22, a P/E/G ratio of 2.37 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. During the same period last year, the firm earned $0.67 EPS. The business's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Annette Bruls sold 2,644 shares of the firm's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,045 shares of company stock valued at $457,749 over the last three months. Company insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new stake in Edwards Lifesciences during the 2nd quarter worth $26,000. 79.46% of the stock is owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source